Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.44 |
| ▸ | MBOAT4 | Q96T53 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 5/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18097672 | 0.86 | MBOAT4 (0.42) | ANO1MBOAT4GAAMAPTHTR2A | |
| SCHEMBL40098 | 0.86 | HDAC3 (0.46) | GAAMAPTHTR2ASLC6A4KCNH2 | |
| SCHEMBL30002118 | 0.86 | HDAC3 (0.46) | GAAMAPTHTR2ASLC6A4KCNH2 | |
| SCHEMBL10235459 | 0.84 | ANO1 (0.45) | ANO1MBOAT4HTR2ASLC6A4KCNH2 | |
| SCHEMBL6498758 | 0.82 | PDCD1 (0.46) | ANO1MBOAT4GAAMAPTHTR2A | |
| SCHEMBL16892265 | 0.82 | MBOAT4 (0.46) | ANO1MBOAT4GAAMAPTHTR2A | |
| SCHEMBL31321848 | 0.82 | PDCD1 (0.46) | ANO1MBOAT4GAAMAPTHTR2A | |
| SCHEMBL40215 | 0.82 | HTR2A (0.46) | ANO1MBOAT4GAAMAPTHTR2A | |
| SCHEMBL28404565 | 0.82 | HTR2A (0.44) | ANO1MBOAT4GAAMAPTHTR2A | |
| SCHEMBL29673193 | 0.82 | HTR2A (0.46) | ANO1MBOAT4GAAMAPTHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577257-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4587424-A1 | YAP/TAZ-TEAD ONCOPROTEINS INHIBITORS | Bridgene Biosciences, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| CN-119894866-A | YAP/TAZ-TEAD oncoprotein inhibitors | 布里奇恩生物科学公司 | 2025-04-25 | — | — | CN | disclosed |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| EP-4474017-A2 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-11 | — | — | EP | disclosed |
| EP-4469446-A1 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-04 | — | — | EP | disclosed |
| CN-118894846-A | Selenium-containing compound and application thereof | 中国药科大学 | 2024-11-05 | — | — | CN | disclosed |
| CN-118791436-A | 2-Aminopyrimidine derivative and preparation method and application thereof | 中国科学院上海药物研究所 | 2024-10-18 | — | — | CN | disclosed |
| EP-3837263-B1 | NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2024-07-03 | — | — | EP | disclosed |
| WO-2024059317-A1 | YAP/TAZ-TEAD ONCOPROTEINS INHIBITORS | BRIDGENE BIOSCIENCES, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| EP-3523277-A1 | SUBSTITUTED PYRROLIDINES AS CFTR MODULATORS | Abbvie S.a.r.l. (LU) | 2019-08-14 | — | — | EP | disclosed |
| WO-2019149657-A1 | BENZYL-, (PYRIDIN-3-YL)METHYL- OR (PYRIDIN-4-YL)METHYL-SUBSTITUTED OXADIAZOLOPYRIDINE DERIVATIVES AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-08-08 | — | — | WO | disclosed |
| WO-2019149660-A1 | TRIAZOLOPYRIMIDINE DERIVATIVES FOR USE AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-08-08 | — | — | WO | disclosed |
| US-20180099932-A1 | Substituted Pyrrolidines and Methods of Use | GALAPAGOS NV (BE) | 2018-04-12 | — | — | US | disclosed |
| WO-2018065921-A1 | SUBSTITUTED PYRROLIDINES AS CFTR MODULATORS | ABBVIE S.Á.R.L. (LU) | 2018-04-12 | — | — | WO | disclosed |
| US-9096558-B2 | N-sulfonylbenzamide compounds | PFIZER LIMITED (GB) | 2015-08-04 | — | — | US | disclosed |
| EP-2590957-B1 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | PFIZER LTD (GB) | 2014-11-12 | — | — | EP | disclosed |
| EP-2590957-A2 | CHEMICAL COMPOUNDS | Pfizer Limited (GB) | 2013-05-15 | — | — | EP | disclosed |
| US-20130109696-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| WO-2012004714-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109696-A1 | Chemical Compounds | SCN1A, SCN7A, SCN1B | ANO1 138/4885MBOAT4 4529/4885GAA 2894/4885 |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | ANO1 4024/4885MBOAT4 3556/4885GAA 2950/4885 |
| US-20180099932-A1 | Substituted Pyrrolidines and Methods of Use | CFTR, PKD1, PKD2 | ANO1 2041/4885MBOAT4 3583/4885GAA 2162/4885 |
| US-12577257-B2 | Heterocyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, CBR3 | ANO1 2312/4885MBOAT4 2926/4885GAA 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.